Mmp inhibitors
CA 2470649 A1 · Owner: Leo Pharma A/S · Inventors: Christensen, Mette Knak; Blaehr, Lars Kristian Albert
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel compounds according to formula I n is 0 1, 2 or 3; X represents , hydroxamic acid (CONHOH) carboxylic acid, phosphonic acid, acetylthiomethyl group or a mercaptomethyl group;R2, R10 and R11 independently represent hydrogen or (Cl_8)alkyl, (CZ_6)alkenyl (C3_$)cycloalkyl, aryl(Co_6)alkyl or , heteroaryl(Co_6)alkyl all of which may optionally be substituted; R3 and R4 independently represent hydrogen, hydroxy or alkoxy; provided that if A A', Z , and R5 are all bonds, and s and t are both 0 (zero) then R6 is different from , hydrogen, and that at least one of R3 R4, R10 and R11 is different from , hydrogen; or a salt hydrate or solvate thereof; pharmaceutical compositions comprising …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 15, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 15, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 15, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.